WSJ reports that "Intermune drug Esbriet has not been approved in the US, but trial results lend hope for approval by the US FDA". "The drug also could potentially treat other diseases and could have more that $1 billion in annual sales as some 100,000 people in the US are affected by the Idiopathic pulmonary fibrosis that the drug addresses". What does this say for the value of ACTC with some 200 million people affected by AMD worldwide and potential for billions in drug sales? Are we not a comparable bet that a bid pharma would be willing to pay $8.5 billion for, especially in light of the other programs in progress at ACTC and their superb science team headed up by the world renowned Dr. Robert Lanza? Investors really have to think about these facts in understanding the true potential value of ACTC...............billions of dollars for sure.
"What does this say for the value of ACTC with some 200 million people affected by AMD worldwide and potential for billions in drug sales?"
It says nothing for ACT! At least until we get a live active management team working there. And the jury is still out on Dr Wotton taking ACT to the promise land. This is his fifth week at ACT, and he's done absolutely nothing to instill confidence that he's the guy.
Keep: The entire team at ACTC, Including Dr. Wotton, are in total lockdown in terms of discussing trial results. That's the deal they worked out and must live by it. Following the article there will be plenty of discussions and focus on our little gem of a company. I share your anxiety for sure and trying to keep control of my patience sitting on a substantial investment that is underwater now for more than 4 years.